CCA
PRNB

Catalyst Capital Advisors’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Catalyst Capital Advisors’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-210
Closed -$7K – 497
2019
Q1 		$7K Hold
210
– – ﹤0.01% 340
2018
Q4 		$6K Hold
210
– – ﹤0.01% 357
2018
Q3 		$6K Buy
+210
New +$5.93K ﹤0.01% 399

Other funds holding PRNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catalyst Capital Advisors's PRNB Position: Q2 2019 in Review

Catalyst Capital Advisors sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q2 2019, closing a stake of 210 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in PRNB in Q3 2018 and held it in 3 quarters. The position peaked at $7K in Q1 2019. 74 funds tracked by Wall St. Rank hold PRNB as of Q2 2019.

  • Catalyst Capital Advisors reported no remaining Principia Biopharma Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 210 Principia Biopharma Inc. Common Stock shares in Q2 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Catalyst Capital Advisors's Principia Biopharma Inc. Common Stock position peaked at $7K in Q1 2019.
  • 74 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q2 2019.

Based on Catalyst Capital Advisors's 13F filing for Q2 2019, filed 8 Aug 2019.